Answers are grounded in this paper and cite their sources.
Investigating EMC2's role in insulin production in pancreatic beta cells, indicating its importance in diabetes therapy.
Introduction and Objective: EMC2 (endoplasmic reticulum membrane complex subunit 2) has recently been found to be downregulated in pancreatic islets from patients with type 2 diabetes mellitus (T2DM), though its functional relevance remains poorly understood. To address this problem, this study aims to investigate whether EMC2 regulates insulin biosynthesis and secretion in pancreatic β-cells. Methods: Min6 cells were transfected with either EMC2-specific or scrambled control siRNAs. Three days after transfection, protein and mRNA expression levels were assessed by Western blotting and quantitative PCR, respectively. Insulin content was measured via ELISA, and overall protein synthesis was evaluated using the SUnSET assay. Transcriptomic changes were analyzed by RNA sequencing. Results: EMC2 deficiency in Min6 cells significantly decreased proinsulin protein levels without affecting Ins1/Ins2 mRNA expression. This reduction was likely attributable to diminished synthesis of its precursor, preproinsulin. Lower puromycin incorporation indicated that loss of EMC2 globally impaired protein synthesis. Under high glucose stimulation, insulin secretion was blunted following EMC2 knockdown, as reflected by a decreased ratio of insulin secreted into the medium relative to cellular content. Notably, protein levels of the translocon and its associated components (Sec61 and TRAP) were clearly reduced. Transcriptome analysis further suggested disrupted ER homeostasis, which may additionally impair the insulin secretory pathway beyond biosynthesis. Conclusion: EMC2 is essential for insulin biosynthesis in pancreatic beta cells. Its downregulation compromises ER function, leading to insulin deficiency, and suggests that EMC2 could represent a potential therapeutic target in diabetes treatment. Disclosure Y. Liu: None. Y. Wang: None. W. Feng: None. M. Liu: None. X. Xu: None. Funding National Natural Science Foundation of China (82370821), Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-3-002C), Tianjin Medical University Clinical Special Disease Research Center - Neuroendocrine Tumor Clinical Special Disease Research Center.
No takes yet. Share an insight, caveat, or question.
LIU et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: